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a  b  s  t  r  a  c  t
Streptococcus  pyogenes  infections  remain  a  health  problem  in  several  countries  because  of  post-
streptococcal  sequelae,  such  as  rheumatic  fever  and rheumatic  heart  disease.  We developed  a  vaccine
epitope  (StreptInCor)  composed  of  55  amino  acid residues  of  the  C-terminal  portion  of the  M  protein
that  encompasses  both  T and  B  cell protective  epitopes.  Recently,  by  using  human  blood  samples,  we
showed  that  the  StreptInCor  epitope  is  able  to bind  to  different  HLA  class  II molecules  and  that  it  couldeywords:
. pyogenes
accine
LA class II transgenic mice
umoral  immune response
be  considered  a universal  vaccine  epitope.  In the  present  work,  we evaluated  the  immune  response  of
HLA  class  II  transgenic  mice  against  aluminum  hydroxide-absorbed  StreptInCor.  After  a period  of  one
year,  several  organs  were  analyzed  histologically  to verify  the  safety  of  the  candidate  vaccine  epitope.
Our  results  showed  that  StreptInCor  is  able  to  induce  robust  and  safe  and  long  lasting  immune  response
without  deleterious  reactions  in  several  organs.  In conclusion,  the  results  presented  here  indicate  that
sidereistopathology StreptInCor  could  be  con
. Introduction
Group A streptococci (GAS) are responsible for several
uman diseases, such as pharyngitis. These diseases may  lead
o post-streptococcal sequelae, including autoimmune disorders
lomerulonephritis and rheumatic fever (RF). Non-autoimmune
ost-streptococcal sequelae that are caused by the cutaneous infec-
ions include necrotizing fasciitis and toxic shock syndrome.
The  global incidence of diseases caused by GAS is not clearly
esolved. In developing countries, many cases go untreated, and
onsequently, the health system is not notiﬁed. Although the esti-
ates are misinformed, it is estimated that there are more than
5 million people around the world with rheumatic heart disease
RHD), the most severe sequel of RF. An estimated 300,000 new
ases of RHD occur each year, and over 200,000 deaths caused by
HD each year [1]. The Brazilian public health system spent over
0 million U.S. dollars for treatment of RF and RHD patients. Fur-
hermore, 31% of all cardiac surgeries in children are related to RF,
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which is also responsible for 7.5% mortality per year. Finally, it is
estimated that Brazil has over 10 million cases of throat infections
caused by Streptococci that lead to 30,000 new cases of RF each
year [2].
The  M protein is the major virulence factor of GAS. The M pro-
tein involves bacterial adhesion, evasion, and promotes immune
responses to GAS because of its immunogenicity [3]. It is composed
of N and C-terminal portions; the N-terminal region is hypervari-
able and highly immunogenic whereas the C-terminal region is
highly conserved among the most GAS strains. The mechanisms
leading to RF and RHD involve a cross-reaction between the N-
terminal region of the alpha-helical coiled-coil M protein and
self-proteins, mainly cardiac proteins. Accordingly, the homology
between the M protein and human proteins myosin, tropomyosin,
keratin [4] and ﬁbrillar collagen, the major component of heart
valves [5], could be involved with the autoimmune response by the
molecular mimicry mechanism [6–11]. In other words, the pro-
duction of cross-reactive antibodies raised against GAS could be
speciﬁcally within cardiac tissue, which would lead to an increased
expression of the adhesion molecule VCAM-I [12] that facilitate
the lymphocytic inﬁltration through the valve surface endothe-
Open access under the Elsevier OA license.lium. This mechanism appears to be the initiating step for tissue
damage and disease pathogenesis [12]. Both streptococcal primed
CD4+ and CD8+ T lymphocytes are recruited probably under spe-
ciﬁc chemokine. This scenario might promote enhanced inﬁltration
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f mononuclear cells to the lesion and the production of inﬂamma-
ory cytokines, such as IFN- and TNF-, resulting in further tissue
estruction and necrosis [12–14].
The triggering of an autoimmune response involves antigenic
resentation by macrophages via human leukocyte antigen-II
HLA-II) molecules to the T cell receptor. These molecules are genet-
cally controlled and some alleles have already been described as
eing associated with the development of RF/RHD. Brieﬂy, DR2 and
R4 were found in association with individuals in America; DR4,
n Saudi Arabia; DR1 and DR6, in South Africa; DR7 and DR11, in
urkey; and DR7 and DR53, in Brazil. It is interesting to note that
 DR7 deﬁned molecular approach was also found in Latvians and
gyptians, and this was associated with the worsening of the valve
amage [15].
The  epidemiological growth of streptococcal diseases and the
igh treatment costs generated by complications caused by RF have
ncouraged many groups to study vaccine candidates to prevent
AS infections. Because of the importance and immunogenicity of
he M protein in GAS infections, some vaccine models against GAS
re being developed that involve different regions of this protein.
 vaccine currently under clinical trials is based on the N-terminal
egion of the M protein and contains sequences from 26 of the most
revalent serotypes of GAS in the USA [16–19]. Additionally, an
ustralian group has developed a vaccine based on a C-terminal B
pitope in the M protein that is conjugated to a universal T epitope
nd Toll-like receptor target lipoproteins [20].
We  have been studying a sequence of amino acids present in the
-terminus of the M protein to develop a subunit vaccine that is able
o induce protection against different GAS strains. To deﬁne the vac-
ine epitope, we tested a large panel of approximately 900 sera and
eripheral blood mononuclear cell (PBMC) samples that enabled
s to identify both B and T immunodominant epitopes and then
o construct a candidate vaccine composed of 55 of these amino
cid residues [21]. Recently, we showed that this vaccine epitope,
dentiﬁed as StreptInCor (medical identity), has three-dimensional
tructural features that make it recognizable to any HLA class II
esulting in T cell activation and differentiation into effectors and
emory cells [22]. Speciﬁc antibodies raised against StreptInCor
ere able to recognize heterologous M1  protein in immunized iso-
enic mice, which suggests that our candidate vaccine has broad
overage.
MHC-II transgenic mouse models have a complete deletion of
urine H2 molecules [23]. These models are an important approach
o study the relationship of HLA-II molecules and autoimmunity
24–27] and therefore could be an important model to study the
mmune response to vaccines. In the present work, MHC  class II
ransgenic mice carrying human HLA class II alleles were evalu-
ted. HLA DRB1.1502 (DR2), DRB1.0401 (DR4), DQB1.0601 (DQ6)
nd DQB1.0302 (DQ8) transgenic mice were used to study humoral
mmune responses after immunization with StreptInCor. These ani-
als were followed for 12 months to monitor the humoral immune
esponses and safety control. The results presented here showed
igh titers of speciﬁc antibodies, and no signs of tissue damage or
utoimmune disorders were observed, indicating that the Strept-
nCor could be an immunogenic and safe vaccine.
. Methods
.1. StreptInCor vaccine epitopeThe vaccine epitope consists of 55 amino acid residues as
ollows: KGLRRDLDASREAKKQLEAEQQKLEEQNKISEASRKGLRRDL-
ASREAKKQVEK, as previously described [21] (patents INPI
501290/0604997-4, PCT-BR07/000184).29 (2011) 8250– 8256 8251
2.2.  Mice
Speciﬁc pathogen-free, 6- to 8-week-old HLA-class II
DRB1*1502 (DR2), DRB1*0401 (DR4), DQB1*0601(DQ6) and
DQB1*0302 (DQ8) transgenic mice were used in this study
[24,25,28]. All transgenic mice were kindly provided by Dr. Chella
S. David (Department of Immunology, Mayo Clinic, Rochester, USA)
and were maintained and manipulated in the animal facility of
the Tropical Medicine Institute, Medical School, University of São
Paulo, Brazil. The mice were housed in autoclaved micro isolator
cages (Alesco, Brazil) and manipulated under aseptic conditions.
All procedures were performed in accordance with the Brazilian
Committee for Animal Care and Use (COBEA) guidelines.
The presence of the HLA-class II transgene in all mice studied
was veriﬁed by molecular biology techniques using skin biopsies.
All mice that did not have the HLA class II transgene were discarded
and were not used in this study. We  also evaluated the presence
of the HLA class II molecules on the surface of antigen presenting
cells from the peripheral blood to control for the expression of the
speciﬁc transgene (data not shown).
2.3. Immunization
HLA-class II transgenic mice received two subcutaneous doses
(100 L) on days 0 and 14 of a suspension containing 50 g
of StreptInCor absorbed onto 300 g of Al(OH)3 (aluminum
hydroxide). Animals receiving saline plus adjuvant were used
as experimental controls for immunization. Sera samples were
obtained from mice on day 28 following immunization while under
light anesthesia by retro-orbital puncture.
2.4. Sera antibody measurement
Sera  antibody titers were determined by ELISA. Brieﬂy, 1 g
of StreptInCor vaccine epitope and overlapping peptides, porcine
cardiac myosin (Sigma, USA), or M1  recombinant protein (clone
kindly provided by Prof Patrick Cleary, University of Minnesota
Medical School, MN,  USA) produced and puriﬁed in our lab,
were diluted in coating buffer (0.05 M carbonate–bicarbonate, pH
9.6, 50 L/w) and was  added to a 96-well MaxiSorp assay plate
(Nunc, Denmark). After overnight incubation, the plates were
blocked with 0.25% gelatin (Sigma) diluted in 0.05% Tween-20
(Sigma, USA) in PBS (dilution buffer) for 1 h at room tempera-
ture. Starting at 1/100 in dilution buffer, serial 2-fold dilutions
were added to the plates (50 L/w). After a 2 h incubation at
37 ◦C and three washes (200 L/w) with 0.05% Tween 20 in PBS
(rinse buffer), the plates were incubated for another hour at 37 ◦C
with peroxidase-conjugated anti-mouse IgG (Pharmingen, USA) at
1:2000 in dilution buffer (50 L/w). The plates were then washed
three times (200 L/w) with rinse buffer, and the reaction was
revealed with 50 L/w of 0.4 mg/mL  ortophenylenediamine (OPD,
Sigma, USA) in 100 mM sodium citrate (Merck, Germany) contain-
ing 0.03% H2O2 (Merck). After 10 min  at room temperature, the
reactions were stopped using 4 N H2SO4, and the optical density
was evaluated using a 490 nm ELISA ﬁlter in an MR4000 ELISA plate
reader (Dynatech, USA). To study IgG isotypes, the biotinylated con-
jugates anti-mouse IgG1, IgG2a, IgG2b and IgG3 (Pharmingen, USA)
were used at 2 g/mL (50 L/w) and incubated for 1 h at 37 ◦C. After
three washes with rinse buffer, the plates were incubated with
streptavidin peroxidase (Pharmingen, USA) at 1/1000 (50 L/w) for
1 h at 37 ◦C. Finally, the reaction was ﬁnished as described above.2.5. Western blot
Lysate  of heart tissue was  obtained from post mortem nor-
mal human myocardium, separated by 10% SDS–PAGE and blotted
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Fig. 1. StreptInCor-reactive IgG isotypes. Sera from HLA class II transgenic mice
(n = 6) immunized with 50 g of StreptInCor absorbed into 300 g of aluminum
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Fig. 2. StreptInCor sequence-speciﬁc antibodies recognize heterologous protein and
did not display crossreactivity with cardiac myosin. Sera from HLA class II transgenic
mice  (n = 6) immunized with 50 g of StreptInCor absorbed into 300 g of aluminum
hydroxide.  The titer obtained for each serum sample is represented as data point.
Titers less than 100 are represented as negative values. DR2 transgenic (tg) mice
(); DR4 tg mice (©); DQ6 tg mice (), and DQ8 tg mice ().
Fig. 3. StreptInCor did not induce heart-tissue proteins cross reactive antibodies. A
pool of sera of each lineage of immunized HLA class II transgenic (Tg) mice was tested
by Western-blot against normal human-myocardium tissue derived proteins. Lane
1: positive control: polyclonal mouse anti-porcine myosin serum; Lane 2: negative
control: non-immunized mouse serum; Lane 3: pool of DR2 Tg-mice (n = 6) sera;ydroxide.  The titer obtained for each serum sample is represented as data point.
iters less than 100 are represented as negative values. DR2 transgenic (tg) mice
); DR4 tg mice (©); DQ6 tg mice (), and DQ8 tg mice ().
nto nitrocellulose membranes as described [29,30]. The blots were
ivided into strips and blocked with Tris buffered saline containing
% of skim milk. The strips were sequentially treated with a pool
f immunized and non-immunized (controls) transgenic mice sera,
ollowed by a treatment with anti-mouse IgG alkaline phosphatase
nd revealed in the presence of NBT-BCIP solution (Invitrogen,
SA). Positive control: mouse anti-porcine myosin serum. Negative
ontrol: pre-immune mouse serum.
.6. Histopathological analysis
After  12 months, immunized mice and controls were sacriﬁced
nd the heart, liver, spleen, brain, kidney and articulations were
ollected. The tissues were immediately ﬁxed in PBS containing 10%
ormaldehyde, parafﬁn-processed, and histological sections were
valuated after staining with hematoxylin and eosin (H&E).
.  Results
.1. StreptInCor induces high IgG antibody titers
StreptInCor was able to induce a robust immune response in
ll HLA class II transgenic mice studied 28 days after immuniza-
ion. DQ6 and DQ8 transgenic mice presented the highest titers of
otal IgG (>1:12,800) (Fig. 1). We  observed variable IgG produc-
ion among the DR4 transgenic mice (>1:800 and 1:12,800) (Fig. 1).
mong the IgG isotypes, IgG1 and IgG2b were induced in all the
ransgenic mice and IgG3 was only produced in the DQ8 transgenic
ice (Fig. 1). Control animals receiving only aluminum hydroxide
id not present any reactivity to StreptInCor (data not shown). To
erify whether the immune response against StreptInCor was spe-
iﬁc, we analyzed the reactivity of the immunized transgenic mice
ecognize the immunogenic vaccine epitope in the heterologous
1 recombinant (rM1) protein. Our results showed that all DR2,
R4, and DQ8 mice and 3 out of 6 DQ6 mice were reactive against
M1 protein (Fig. 2). It is interesting to note that the levels of anti-
gG antibodies against rM1  protein were lower (1:100 to 1:3200)
Fig. 2). Additionally, none of the transgenic mice developed anti-
odies against either porcine cardiac myosin (Fig. 2) or human
yocardium-derived proteins (Fig. 3) indicating the absence of
ross-reactivity with cardiac proteins.
All the mice were followed for one year before they were sacri-
ced. The amount of IgG was evaluated at 1, 4, 8, and 12 months. Our
esults showed a decreased amount of IgG present in immunized
ice after 4 months (Fig. 4), and most of the mice maintainedLane 4: pool of DR4 Tg-mice (n = 6) sera; Lane 5: pool of DQ6 Tg-mice (n = 6) sera;
Lane 6: pool of DQ8 Tg-mice (n = 6) sera.
low reactivity IgG titers until 1 year post-immunization
(Fig.  4).
3.2.  Immunized HLA class II transgenic mice recognize
StreptInCor overlapping peptidesWe analyzed the humoral immune response of HLA class II Tg-
mice against 8 StreptInCor-derived overlapping peptides that cover
the entire vaccine epitope sequence and encompassed the possi-
bilities of processing and presentation by antigen-presenting cells
M.T. Guerino et al. / Vaccine 29 (2011) 8250– 8256 8253
Fig. 4. Evaluation of humoral immune responses. Sera from immunized HLA class II transgenic (Tg) mice (n = 6) followed for 1 year. The titer obtained for each serum sample
at  1 (), 4 (), 8 (©), and 12 months (). Titers less than 100 are represented as negative values.
Table  1
Immune recognition of overlapping M protein C-terminal peptides.
Overlapping peptides sequences (20 aa residues) Transgenic mice bearing HLA class II alleles humoral immune response (IgG)
DR2 DR4 DQ6 DQ8
KGLRRDLDASREAKKQLEAE 6+/6 5+/6 2+/6 5+/6
KGLRRDLDASREAKKQVEKA 5+/6 5+/6 3+/6 4+/6
GLRRDLDASREAKKQVEKAL 5+/6 5+/6 2+/6 3+/6
LDASREAKKQLEAEQQKLEE 4+/6 5+/6 3+/6 6+/6
KLEEQNKISEASRKGLRRDL 5+/6 4+/6 3+/6 5+/6
KISEASRKGLRRDLDASREA 5+/6 2+/6 2+/6 3+/6
SEASRKGLRRDLDASREAKK 5+/6 4+/6 3+/6 5+/6
ASRKGLRRDLDASREAKKQV 4+/6 4+/6 1+/6 2+/6
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tumoral immune response of six transgenic mice for each lineage after 28 days post-
escribed by us [21,22]. Positive immune response was  considered when antibodie
APCs) as previously described [22]. Our results were similar to
hose observed in humans. Both, HLA-DR and -DQ Tg-mice rec-
gnized most of the peptides (Table 1). It was interesting to note
hat the immune response was more frequent in mice bearing HLA-
R molecules than in those bearing HLA-DQ, the second molecule
Table 1). Titles of antibodies varied from 1:100 to 1:3200 (data not
hown).
.3. StreptInCor does not induce deleterious reactions
The safety of the vaccine epitope was evaluated by analyzing
he histopathology of several organs in mice 1 year after immu-
ization (Fig. 4). No autoimmune or pathological reactions were
bserved in the heart or other organs (Fig. 5) because of the
mmunization with StreptInCor and alum. However, some vacci-
ated transgenic mice (10 out of 24) and those that only received
luminum hydroxide in saline (9 out of 24) developed defective
ematopoiesis, hepatic steatosis, or presented mononuclear inﬁl-
ration (Table 2).nization was  tested by ELISA against overlapping peptides sequences, as previously
s were ≥1:100 and ≤1:3200.
4. Discussion
We  developed a vaccine epitope (StreptInCor) composed of 55
amino acid residues of the C-terminal portion of the M protein
that encompasses both T and B cell-protective epitopes [21]. The
structural, chemical, and biological properties of this peptide were
evaluated, and we show that StreptInCor is a very stable molecule,
which is an important property for a vaccine candidate. Addition-
ally, our previous results show that humans, bearing different HLA
class II molecules recognize StreptInCor, which demonstrates the
universal character of this vaccine [22]. It is interesting to note that
both healthy individuals and rheumatic fever and rheumatic heart
disease patients were able to respond to StreptInCor peptide. No
cross reactivity against human myocardium and valve proteins was
observed, indicating that StreptInCor is immunogenic and safe [21].
The role of HLA class II molecules in the antigen presenta-
tion and that this vaccine should avoid autoimmune reactions,
were considered in the present work; therefore, we  evaluated the
capacity of HLA class II transgenic mice to recognize the vaccine
epitope combined with aluminum hydroxide adjuvant while not
inducing autoimmune reactions. This adjuvant has been used in
8254 M.T. Guerino et al. / Vaccine 29 (2011) 8250– 8256
Fig. 5. Histological analysis of tissues from immunized HLA class II transgenic mice. (A) Histological sections of the heart chambers, (10×); (B) tricuspid valve (25×); (C)
m leen (
L  joint 
*
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w
iitral valve (50×); (D) aortic valve (25×); (E) joint (25×); (F) kidney (200×); (G) sp
V, left ventricle; S, septum; A, aortic valve; T, tricuspid valve; M, mitral valve; JC,
*moderate ***intense. H&E, hematoxylin and eosin stain.
eterinarian and human vaccines since 1930 and causes very little
ystemic toxicity [31].The  presence of the HLA class II transgene will affect the immune
esponse in the whole mouse since thymic selection will interfere
ith the interactions between T lymphocytes and antigen present-
ng cells and with the activation of B lymphocytes in the periphery.400×); (H) brain, and (I) liver. RA, right atrium; RV, right ventricle; LA, left atrium;
cavity; ST, synovial tissue; BM,  bone marrow; EH, extramedullary hematopoiesis;
The  biological properties of HLA class II molecules, together with
testing their role in a transgenic mice model, are useful for new
vaccine studies. Recently, our group showed that the HLA class
II transgenic mice are able to respond to multi-epitopic vaccines
against HIV by inducing proliferation of both CD4+ and CD8+ T
lymphocytes and the production of IFN [32].
M.T. Guerino et al. / Vaccine 29 (2011) 8250– 8256 8255
Table 2
Histopathological analysis.
HLA class II tg mice Immunization Gender Number Kidney Spleen Liver Bone marrow (% cells)
DR2 StreptInCor + Alum F 6 2 EHa 1 EHb
1 Sta 98–100
1 Stc
Saline + Alum F 6 1 EHa 1 Sta 90–100
1 Stb
1 Stc
DR4 StreptInCor + Alum F 6 1 MNL  2 EHa 90–100
Saline + Alum M 2 1 EHb 2 EHb 90–100
F 4 1  MNL 3 EHa 2 EHa
DQ6 StreptInCor + Alum M 5 1 EHb 98–100
F 1
Saline + Alum F 4 2 EHa 1 EHb 98–100
DQ8  StreptInCor + Alum M 6 1 EHa 3 EHa 100
2 EHc
Saline + Alum M 4 1 EHa 1 EHa 100
1 EHb 1 EHb
1 EHc 1 EHc
tg – transgenic mice; MNL  – mononuclear inﬁltration; EH – extramedullary hematopoiesis; St – steatosis
a Mild.
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c Intense.
The data presented here show that all HLA class II transgenic
ice (DR2, DR4, DQ6 and DQ8) immunized with StreptInCor plus
luminum hydroxide were able to produce speciﬁc IgG antibodies
hat also recognize the vaccine epitope in the context of a heterolo-
ous M protein. According to our previous data on human sera and
eripheral blood cells [22], the results presented here also indicated
hat antigen presenting cells of HLA class II transgenic mice bear-
ng DR2, DR4, DQ6 and DQ8 molecules were able to present several
eptides encompassed by StreptInCor vaccine epitope, probably via
he TCR with activation of both T and B lymphocytes. In addition,
t is interesting to note that transgenic mice bearing the HLA-DR
olecules were more responsive than those bearing the second
LA class II molecules (DQ6 or DQ8). In agreement with these
ata the IgG speciﬁc responses in DR2 and DR4 transgenic mice
ere slightly better than in mice bearing DQ6 and DQ8 molecules.
lthough some mice became nonresponsive a year after the immu-
ization, the immune responses to StreptInCor were maintained
or up to a year. These results also indicated that the vaccine epi-
ope is able to induce a long period of speciﬁc immune responses,
ith IgG1 predominance due to the effects of the adjuvant. The bal-
nce between humoral and cellular immune responses induced by
djuvant formulations can be addressed through the isotype pro-
le of the vaccine-speciﬁc IgG1 and IgG2a antibodies produced.
he IgG1 isotype switch is dependent of IL-4 production in oppo-
ite to isotype IgG2a, which is IFN- dependent. We  observed a
uge predominance of speciﬁc IgG1 when compared to IgG2a and
lso to IgG3, another IFN- dependent isotype. It is interesting to
ote that some IgG2b, a TGF--depending switch, was seen in some
nimals from all groups studied (DR2, DR4, DQ6 and DQ8). Finally,
luminum adjuvants are responsible for Th2 polarization, resulting
n increased humoral immunity, mediated by production of IgG1
sotype.
Considering pharyngitis is among the most common S. pyogenes
nfections, the induction of mucosal immune responses, mainly by
gA secretions, is attractive. Accordingly, other adjuvants are being
ssayed to obtain both systemic and mucosal immune responses.
ne of the major challenges of producing a vaccine against to S.
yogenes is to not induce autoimmune responses and diseases such
s RF and RHD. Although we know the mechanisms that lead the
isease in humans [13], there have been no ideal in vivo models of
he disease, except for in the Lewis rat [33], until our current study.
As myosin is a putative auto-antigen involved in RHD develop-
ent [33–39], we used both human myocardium-derived proteinsand  porcine cardiac myosin to evaluate the presence of cross-
reactive antibodies that could be triggered by the immunizations.
No speciﬁc cross reactivity against heart proteins was observed
indicating that StreptInCor did not induce autoimmune reactions.
Myosin  heavy chains have been categorized into several classes
based on comparisons and phylogenetic analysis of the conserved
regions [40–42]. It is interesting to note that the coiled coil region
differs among the species studied however global results suggested
a common coevolution of myosin head, neck and tail domains
[40–42]. So, the fact that we  used both porcine myosin and human
cardiac protein extract, in which cardiac myosin is the major pro-
tein, strongly indicated that StreptInCor vaccine epitope is unable
of inducing autoimmune reactions.
Although the histopathology of mice assessed a year after
the last immunization showed some alterations, such as
extramedullary hematopoiesis, liver steatosis, and inﬁltration of
mononuclear cells in the kidney, these observations were also
observed in the control animals. This ﬁnding suggests that these
features are not due to the immunization with the vaccine epitope
and are most likely due to aging of the mice. In support of this
ﬁnding, the analysis of the heart tissue, with a special focus on the
valves, and the other organs after 1 year did not display any speciﬁc
RF lesions.
Despite these promising results, humans are the only hosts for
GAS. Although several studies have been conducted to ﬁnd a suit-
able animal model, there is no suitable animal model that can
desiccate the autoimmune process of RF and RHD.
5.  Conclusions
All the results presented here indicate that the StreptInCor vac-
cine epitope induces a robust and long lasting immune response in
transgenic mice and not induces autoimmune reactions and can be
considered a promising vaccine candidate to prevent RF.
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